Kymera Investor Presentation Deck

As of October 20, 2023 No dose-limiting toxicities across dose levels 1-3 Adverse events related to KT-253 and observed in at least 2 patients Nausea (n=3): Grade 1 (n=2) and Grade 2 (n=1) Diarrhea (n=2): All Grade 1 ● ● ● ● ● ● Serious adverse events (SAEs) deemed related to KT-253: Hypotension (n=1): Grade 3, occurred during cycle 4 Due to decreased oral intake; resolved with treatment including IV fluids Patient remains on study without dose reduction or recurrence of hypotension No thrombocytopenia or neutropenia even after 6 cycles of KT-253 ● KT-253 Phase 1a: Safety Update ● ● KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 40

View entire presentation